Literature DB >> 26722023

Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis.

Franco Lumachi1, Giordano B Chiara2, Renato Tozzoli3, Alessandro Del Conte4, Alessandro Del Contea, Stefano M M Basso2.   

Abstract

Liver and pulmonary metastases (PMs) are relatively common in patients with colorectal cancer. The majority of metastases are suitable for surgical resection, and the effectiveness of metastasectomy is usually assessed based on overall survival (OS). Metastasectomy provides a mean 5-year OS rate of approximately 50%, but the results are better in patients with liver metastases compared to those with PMs. Unfortunately, the presence of bilateral or multiple PMs represents a relative contraindication to surgical metastasectomy. Unresectable PMs can be safely treated with percutaneous radiofrequency ablation or radiotherapy, but the reported results vary widely. Several clinical prognostic factors affecting OS after metastasectomy have been reported, such as number of PMs, hilar or mediastinal lymph node involvement, disease-free interval, age and gender, resection margins, size of the metastases, neoadjuvant chemotherapy administration, and histological type of the primary cancer. The accurate evaluation of all clinical prognostic factors, circulating and immunohistochemical markers, and the study of gene mutational status will lead to a more accurate selection of patients scheduled to metastasectomy, with the aim of improving outcome. Copyright
© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

Entities:  

Keywords:  Colorectal cancer; lung metastases; metastatic colorectal cancer; prognostic factor; pulmonary metastases; review

Mesh:

Substances:

Year:  2016        PMID: 26722023

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

Review 1.  The primary tumor location in colorectal cancer: A focused review on its impact on surgical management.

Authors:  Yuzo Nagai; Tomomichi Kiyomatsu; Yoshimasa Gohda; Kensuke Otani; Katsuya Deguchi; Kazuhiko Yamada
Journal:  Glob Health Med       Date:  2021-12-31

2.  Patients with colorectal lung oligometastases (L-OMD) treated by dose adapted SABR at diagnosis of oligometastatic disease have better outcomes than patients previously treated for their metastatic disease.

Authors:  Alina Mihai; Yijia Mu; John Armstrong; Mary Dunne; Sushil Beriwal; Luke Rock; Pierre Thirion; Dwight E Heron; Brian Healy Bird; Jennifer Westrup; Conleth Gerard Murphy; M Saiful Huq; Raymond McDermott
Journal:  J Radiosurg SBRT       Date:  2017

3.  The impact of pulmonary metastasectomy in patients with previously resected colorectal cancer liver metastases.

Authors:  Armin Wiegering; Johannes Riegel; Johanna Wagner; Volker Kunzmann; Johannes Baur; Thorsten Walles; Ulrich Dietz; Stefan Loeb; Christoph-Thomas Germer; Ulrich Steger; Ingo Klein
Journal:  PLoS One       Date:  2017-03-22       Impact factor: 3.240

4.  Clinical Application of CT-Guided Percutaneous Microwave Ablation for the Treatment of Lung Metastasis from Colorectal Cancer.

Authors:  Lin Li; Ketong Wu; Haiyang Lai; Bo Zhang
Journal:  Gastroenterol Res Pract       Date:  2017-10-31       Impact factor: 2.260

Review 5.  Contemporary Management of Locally Advanced and Recurrent Rectal Cancer: Views from the PelvEx Collaborative.

Authors: 
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.575

6.  Reply from author: What is the right answer for pulmonary metastatic disease? More clinical trials.

Authors:  Mara B Antonoff
Journal:  JTCVS Open       Date:  2021-09-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.